TY - JOUR
T1 - Defining drug response for stratified medicine
AU - Lonergan, Mike
AU - Senn, Stephen J.
AU - McNamee, Christine
AU - Daly, Ann K.
AU - Sutton, Robert
AU - Hattersley, Andrew
AU - Pearson, Ewan
AU - Pirmohamed, Munir
N1 - The article is based on a workshop held by the UK Pharmacogenetics and Stratified Medicine Network (www.uk-pgx-stratmed.co.uk/), which was funded by the Knowledge Transfer Network and Innovate UK at the time of the workshop. M.P. is an NIHR Senior Investigator and acknowledges the support of the MRC Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine, both in Liverpool. R.S. is also an NIHR Senior Investigator, and acknowledges the support of the NIHR Liverpool Pancreas Biomedical Research Unit. S.J.S. gratefully acknowledges funding through grant 602552 for the IDEAL project under the European Union FP7 programme.
PY - 2017/1
Y1 - 2017/1
N2 - The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.
AB - The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.
U2 - 10.1016/j.drudis.2016.10.016
DO - 10.1016/j.drudis.2016.10.016
M3 - Review article
C2 - 27818254
SN - 1359-6446
VL - 22
SP - 173
EP - 179
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 1
ER -